InflaRx N.V. (IFRX)
NASDAQ: IFRX · Real-Time Price · USD
1.790
+0.120 (7.19%)
May 13, 2025, 4:00 PM - Market closed

Revenue by Product

Fiscal year is January - December.
Fiscal Year
FY 2023
Period Ending
Dec '23
Monoclonal Antibodies
68.21K

Revenue by Geography

Fiscal year is January - December.
Fiscal Year
FY 2023
Period Ending
Dec '23
United States
68.21K